Cargando…

A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants

Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease inhibitor, telaprevir. Variant fitness was est...

Descripción completa

Detalles Bibliográficos
Autores principales: Adiwijaya, Bambang S., Herrmann, Eva, Hare, Brian, Kieffer, Tara, Lin, Chao, Kwong, Ann D., Garg, Varun, Randle, John C. R., Sarrazin, Christoph, Zeuzem, Stefan, Caron, Paul R.
Formato: Texto
Lenguaje:English
Publicado: Public Library of Science 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855330/
https://www.ncbi.nlm.nih.gov/pubmed/20419154
http://dx.doi.org/10.1371/journal.pcbi.1000745
_version_ 1782180171246206976
author Adiwijaya, Bambang S.
Herrmann, Eva
Hare, Brian
Kieffer, Tara
Lin, Chao
Kwong, Ann D.
Garg, Varun
Randle, John C. R.
Sarrazin, Christoph
Zeuzem, Stefan
Caron, Paul R.
author_facet Adiwijaya, Bambang S.
Herrmann, Eva
Hare, Brian
Kieffer, Tara
Lin, Chao
Kwong, Ann D.
Garg, Varun
Randle, John C. R.
Sarrazin, Christoph
Zeuzem, Stefan
Caron, Paul R.
author_sort Adiwijaya, Bambang S.
collection PubMed
description Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease inhibitor, telaprevir. Variant fitness was estimated using a model in which variants were selected by competition for shared limited replication space. Fitness was represented in the absence of telaprevir by different variant production rate constants and in the presence of telaprevir by additional antiviral blockage by telaprevir. Model parameters, including rate constants for viral production, clearance, and effective telaprevir concentration, were estimated from 1) plasma HCV RNA levels of subjects before, during, and after dosing, 2) post-dosing prevalence of plasma variants from subjects, and 3) sensitivity of variants to telaprevir in the HCV replicon. The model provided a good fit to plasma HCV RNA levels observed both during and after telaprevir dosing, as well as to variant prevalence observed after telaprevir dosing. After an initial sharp decline in HCV RNA levels during dosing with telaprevir, HCV RNA levels increased in some subjects. The model predicted this increase to be caused by pre-existing variants with sufficient fitness to expand once available replication space increased due to rapid clearance of wild-type (WT) virus. The average replicative fitness estimates in the absence of telaprevir ranged from 1% to 68% of WT fitness. Compared to the relative fitness method, the in vivo estimates from the viral dynamic model corresponded more closely to in vitro replicon data, as well as to qualitative behaviors observed in both on-dosing and long-term post-dosing clinical data. The modeling fitness estimates were robust in sensitivity analyses in which the restoration dynamics of replication space and assumptions of HCV mutation rates were varied.
format Text
id pubmed-2855330
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-28553302010-04-23 A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants Adiwijaya, Bambang S. Herrmann, Eva Hare, Brian Kieffer, Tara Lin, Chao Kwong, Ann D. Garg, Varun Randle, John C. R. Sarrazin, Christoph Zeuzem, Stefan Caron, Paul R. PLoS Comput Biol Research Article Variants resistant to compounds specifically targeting HCV are observed in clinical trials. A multi-variant viral dynamic model was developed to quantify the evolution and in vivo fitness of variants in subjects dosed with monotherapy of an HCV protease inhibitor, telaprevir. Variant fitness was estimated using a model in which variants were selected by competition for shared limited replication space. Fitness was represented in the absence of telaprevir by different variant production rate constants and in the presence of telaprevir by additional antiviral blockage by telaprevir. Model parameters, including rate constants for viral production, clearance, and effective telaprevir concentration, were estimated from 1) plasma HCV RNA levels of subjects before, during, and after dosing, 2) post-dosing prevalence of plasma variants from subjects, and 3) sensitivity of variants to telaprevir in the HCV replicon. The model provided a good fit to plasma HCV RNA levels observed both during and after telaprevir dosing, as well as to variant prevalence observed after telaprevir dosing. After an initial sharp decline in HCV RNA levels during dosing with telaprevir, HCV RNA levels increased in some subjects. The model predicted this increase to be caused by pre-existing variants with sufficient fitness to expand once available replication space increased due to rapid clearance of wild-type (WT) virus. The average replicative fitness estimates in the absence of telaprevir ranged from 1% to 68% of WT fitness. Compared to the relative fitness method, the in vivo estimates from the viral dynamic model corresponded more closely to in vitro replicon data, as well as to qualitative behaviors observed in both on-dosing and long-term post-dosing clinical data. The modeling fitness estimates were robust in sensitivity analyses in which the restoration dynamics of replication space and assumptions of HCV mutation rates were varied. Public Library of Science 2010-04-15 /pmc/articles/PMC2855330/ /pubmed/20419154 http://dx.doi.org/10.1371/journal.pcbi.1000745 Text en Adiwijaya et al. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Adiwijaya, Bambang S.
Herrmann, Eva
Hare, Brian
Kieffer, Tara
Lin, Chao
Kwong, Ann D.
Garg, Varun
Randle, John C. R.
Sarrazin, Christoph
Zeuzem, Stefan
Caron, Paul R.
A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
title A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
title_full A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
title_fullStr A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
title_full_unstemmed A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
title_short A Multi-Variant, Viral Dynamic Model of Genotype 1 HCV to Assess the in vivo Evolution of Protease-Inhibitor Resistant Variants
title_sort multi-variant, viral dynamic model of genotype 1 hcv to assess the in vivo evolution of protease-inhibitor resistant variants
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2855330/
https://www.ncbi.nlm.nih.gov/pubmed/20419154
http://dx.doi.org/10.1371/journal.pcbi.1000745
work_keys_str_mv AT adiwijayabambangs amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT herrmanneva amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT harebrian amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT kieffertara amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT linchao amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT kwongannd amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT gargvarun amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT randlejohncr amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT sarrazinchristoph amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT zeuzemstefan amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT caronpaulr amultivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT adiwijayabambangs multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT herrmanneva multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT harebrian multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT kieffertara multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT linchao multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT kwongannd multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT gargvarun multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT randlejohncr multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT sarrazinchristoph multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT zeuzemstefan multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants
AT caronpaulr multivariantviraldynamicmodelofgenotype1hcvtoassesstheinvivoevolutionofproteaseinhibitorresistantvariants